Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    22825216 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting PONATINIB for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Conditions: Chronic Myeloid Leukemia (CML);   Ph+ Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Ponatinib 45 mg QD
2 Completed Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Condition: Chronic Myeloid Leukemia
Intervention: Drug: DCC-2036
3 Completed
Has Results
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Bosutinib;   Drug: imatinib

Indicates status has not been verified in more than two years